Literature DB >> 20846680

Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study.

Christian Seitz1, Amit Gupta, Shahrokh F Shariat, Kazumasa Matsumoto, Wassim Kassouf, Thomas J Walton, Hans-Martin Fritsche, Wolfgang Otto, Stefan Tritschler, Patrick J Bastian, Joaquin Carballido, Vincenzo Ficarra, Pierre I Karakiewicz, Walter Artibani, Guido Mazzoleni, Giacomo Novara.   

Abstract

PURPOSE: Tumor necrosis is associated with a poor oncological outcome in patients with upper tract urothelial carcinoma and other malignancies. We validated the association of tumor necrosis with pathological features and clinical outcomes in a large international cohort of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.
MATERIAL AND METHODS: This retrospective study included 754 patients treated with radical nephroureterectomy at a total of 9 centers. Tumor necrosis was scored as greater than 10% of tumor area based on microscopic evaluation.
RESULTS: Tumor necrosis was present in 165 specimens (21.9%). The prevalence of tumor necrosis increased with advancing pathological stage, including 7%, 10.6% and 50% for T1, T2 and T3-4, respectively (p <0.001). Tumor necrosis was associated with features of aggressive upper tract urothelial carcinoma, such as high grade, lymph node metastasis, lymphovascular invasion, sessile tumor architecture and concomitant carcinoma in situ (p <0.002). Median followup in censored patients was 40 months (IQR 18 to 75). On univariate Cox regression analysis tumor necrosis was significantly associated with disease recurrence and cancer specific mortality (HR 2.4 and 2.7, p <0.001). However, on multivariate Cox regression analysis including patient age, stage, grade, lymph node status, lymphovascular invasion and adjuvant chemotherapy tumor necrosis was not associated with disease recurrence (HR 1.1, p = 0.49) or cancer specific mortality (HR 1.1, p = 0.51). Excluding 63 patients who received adjuvant chemotherapy and/or 49 with positive lymph nodes did not substantially change these results.
CONCLUSIONS: In this large, multicenter international study tumor necrosis was associated with pathological features of biologically aggressive upper tract urothelial carcinoma. However, tumor necrosis was not an independent predictor of clinical outcomes.
Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20846680     DOI: 10.1016/j.juro.2010.06.106

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  [Urothelial carcinoma of the upper urinary tract: clinical and pathological criteria and their predictive implications after radical nephroureterectomy].

Authors:  Christian Seitz; Paul Schramek
Journal:  Wien Med Wochenschr       Date:  2011-08

Review 2.  [Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].

Authors:  M Rink; M Adam; J Hansen; F K Chun; S A Ahyai; M Remzi; T Schlomm; O Engel; R Heuer; C Eichelberg; M Fisch; R Dahlem; S F Shariat
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

3.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 4.  Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.

Authors:  Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

Review 5.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

6.  [Elective organ and function preservation in ureter and renal pelvis tumors].

Authors:  S Rausch; G Gakis; J Bedke; A Stenzl
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

7.  Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma.

Authors:  Yue Wang; Jinxia Zhang; Yunfan Wang; Shufang Wang; Yu Zhang; Qi Miao; Fei Gao; Huiying He
Journal:  Front Med       Date:  2019-04-24       Impact factor: 4.592

Review 8.  The role of extensive lymphadenectomy in upper tract malignant disease.

Authors:  Travis Pagliara; Andrew Nguyen; Badrinath Konety
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

9.  The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy.

Authors:  Qi Tang; Gengyan Xiong; Xuesong Li; Dong Fang; Chenguang Xi; Lei Zhang; Kaiwei Yang; Lin Yao; Cuijian Zhang; Wei Yu; Qun He; Kan Gong; Zhisong He; Liqun Zhou
Journal:  World J Urol       Date:  2015-10-24       Impact factor: 4.226

Review 10.  The role of systemic chemotherapy in management of upper tract urothelial cancer.

Authors:  Bishoy A Gayed; Gregory R Thoreson; Vitaly Margulis
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.